Oncology Multiple Articles & Analysis
7 articles found
ENPP2 Catalytic Features (Structured Summary) Feature Description Functional Implication Phosphodiesterase Domain Hydrolyzes LPC to LPA Generates bioactive lipid signals Somatomedin B-like Domains Bind integrins/ECM Localizes enzyme activity to specific microenvironments Substrate Specificity Preference for LPC acyl chain length Determines LPA species and downstream receptor activation ...
Clinical Relevance: From Autoimmunity to Oncology In autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease, CCR1 signaling sustains leukocyte infiltration into tissues. ...
These innovative therapies are engineered to simultaneously bind to multiple targets, enhancing efficacy against complex diseases. For instance, bispecific antibodies can engage both immune cells and cancer cells, facilitating targeted destruction of malignant cells while sparing healthy tissue. Such therapies have shown promise in clinical trials, particularly in ...
Luminex technology is a powerful tool for cytokine profiling in oncology research. It is a bead-based assay system that allows the simultaneous measurement of multiple cytokines in a single sample. ...
Luminex technology is a powerful tool for cytokine profiling in oncology research. It is a bead-based assay system that allows the simultaneous measurement of multiple cytokines in a single sample. ...
When promising drug candidates are identified for further investigation in clinical trials, sponsor companies are usually optimistic about outcomes. But there are times, when after years of sunk effort and resources, clinical trials fail to bring a viable drug to market. Frequently, a drug fails for safety or efficacy reasons that are beyond a sponsor’s control. However, to some degree, ...
Lymphocyte-activation gene 3 (LAG-3), also known as CD233, is a type I transmembrane protein expressed mainly in activated T cells, NK cells, B cells, and plasma cell-like DCs. Oncology and autoimmune diseases (rheumatoid arthritis, multiple sclerosis) are currently among the clinical pipeline indications for LAG-3 which acts as an immunomodulator in a variety of ...